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Abstract
Background: Dyslipidemia is a common disorder in systemic lupus erythematosus (SLE) patients. It is still inconclusive whether
antimalarial drugs could affect the serum lipids in SLE patients, therefore we conducted a systematic review and meta-analysis of
available data to address this issue.
Methods:We comprehensively searched the databases of PubMed, EMBASE and Cochrane Library from date of inception to Sep
2018 for both randomized controlled trials (RCTs) and observational studies. ReviewManager 5.3 software was used for analysis. We
performedmeta-analysis using random-effects model and weighted the mean difference (WMD) and its 95% conﬁdence interval (CI).
The Q test was used to assess the presence of heterogeneity and the I2 index was used to quantify the extent of heterogeneity.
Results: In total, 8 studies met our selection criteria including 2 RCTs, 2 cohort studies, and 4 case-control studies. There were 717
patients (336 patients in CQ (chloroquine) or HCQ (hydroxychloroquine) group, and 381 patients in control group (SLE patients
without the therapy of AM)). Compared with the control group, TC, TG, LDL-C, VLDL-C were associated with a signiﬁcant decrease,
respectively (WMD=21.40mg/dL, 95% CI 27.62 to 15.18, P< .00001), (WMD=29.07mg/dL, 95% CI 45.28 to 12.86,
P= .0004), (WMD=16.25mg/dL, 95% CI 28.82 to 3.68, P= .01), (WMD=6.41mg/dL, 95% CI 12.39 to 0.44, P= .04),
however the change of HDL-C did not reach statistically signiﬁcance (WMD=4.42mg/dL, 95% CI 1.21 to 10.06, P= .12).
Conclusions:CQ or HCQ can infect the serum lipids in SLE patients. However, these results should be interpreted with cautions
since lacking sufﬁcient RCTs.
Abbreviations: CI = conﬁdence interval, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein
cholesterol, RCTs = randomised controlled trials, SLE = systemic lupus erythematosus, TC = cholesterol, TG = triglyceride, VLDL-C
= very low-density lipoprotein cholesterol, WMD = weighted the mean difference.
Keywords: antimalarial, meta-analysis, serum lipids, systemic lupus erythematosus
[5–7]1. Introduction
SLE is a chronic autoimmune disease with multiple system
impairments that can be severe and threaten patients’ life.[1–3]
The morbidity of SLE was 8.3/100,000/year for females and 1.4/
100,000/year for males.[4] Premature atherosclerosis and subse-
quent progressions have become the leading cause of death inEditor: Worawit Louthrenoo.
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1patients with SLE. Dyslipidemia is one of the traditional risk
factors for atherosclerosis,[8,9] and it is a very frequent
comorbidity in SLE patients with negative effects in the long
term,[10,11] which not only increases the risk of cardiovascular
disease but also affects other clinical symptoms of SLE patients,
such as accelerating chronic kidney disease process and damaging
brain function. There are also some conditions which inﬂuenceta are available in the respective articles.
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Tao et al. Medicine (2019) 98:14 Medicinedyslipidemia prevalence, such as auto-antibody in lipoprotein
metabolism, renal involvement, disease activity and increased
lipid level due to drugs.[6,12,13] Tselios et al reported that the
prevalence of dyslipidemia was 36% among newly diagnosed
SLE patients, and 60% or even higher after 3 years.[14]
Antimalarials are the old drugs used in clinics. CQ and HCQ are
common antimalarials, CQ was introduced in 1953, and HCQ in
1955.[15] These 2 kinds of drugs are both 4-amino-quinolines,HCQ
is an analog of CQ. These 2 compounds have many similarities in
pharmacological function and biological mechanism.[16] Nowa-
days, CQ and HCQ are widely used in SLE patients.[17–20]
The use of CQ or HCQ may be associated with lower levels of
serum lipid in SLE patients, especially among those who were on
steroids. In 1990, Wallace et al had suggested that HCQ therapy
had a signiﬁcantly statistical association with serum lipids
reduction in SLE patient.[21] However, Tam et al had reported
that HCQ has no signiﬁcant effect on lipid in Chinese lupus
patients in 2000.[22] Since then, there were some studies on this,
but the evidences are insufﬁcient and inconclusive. We, therefore,
performed a systematic review and meta-analysis to evaluate the
impact of CQ or HCQ on serum lipids in SLE patients.
2. Methods
2.1. Search strategy
In order to identify all available studies, the study was performed
according to PRISMA (preferred reporting items for systematic
review and meta-analysis) guidelines.[23] We searched all
literatures in PubMed, Cochrane Databases and EMBASE (up
to September 2018). There were no limitations on language or
publication date. Literature search was performed using the
following search terms in all possible combinations: systemic
lupus erythematosus (SLE), lupus erythematosus disseminatus,
lupus, SLE, Antimalarials, Hydroxychloroquine, chloroquine,
lipid (see search strategy for PubMed in online supplementary
ﬁle, http://links.lww.com/MD/C902). In addition, all the refer-
ences in the retrieved literatures were manually reviewed to
identify other potentially relevant articles.
2.2. Study selection
The following inclusive selection criteria were applied:1. study design: RCTs, cohort or case-control studies with
detailed data,
study population: the diagnosis of patients was fulﬁlled the2.
American College of Rheumatology (ACR) criteria for SLE,
without diseases caused by dyslipidemia and the current
taking lipid-lowering drugs,
comparison intervention: with and without CQ or HCQ,3.
4. outcome measure: serum lipids (TC, TG, LDL-C, HDL-C, and
VLDL-C). In the case of duplicate data publication (several
studies with overlapping samples), we only included the most
informative article or complete study to avoid duplication of
information.
2.3. Date extraction and quality assessment
In each study, the following data items were extracted:(1)
(2)ﬁrst author’s name,
year of publication,(3) study design,
(4) population,2(5) number of participants in the CQ or HCQ and control
groups,
age, weight of study participants,(6)
(7) duration of SLE,
(8) mean dose of drug,
(9) level of serum lipids.A systematic assessment of bias in the included RCTs’ studies
was performed using the Cochrane criteria.[24] We assessed the
authenticity and quality of the included observational studies by
Newcastle-Ottawa scales (NOS).[25] The scoring system encom-
passes a resulting score range between 0 and 9 with a higher score
representing a better methodological quality.[26] Two investi-
gators (Chen Yang Tao and Jin Shang) carried out the literature
search, study selection, data extraction and quality assessment
independently. Any discrepancies were resolved by consensus.
2.4. Statistical analysis and risk of bias assessment
All statistical analysis was conducted by Review Manager 5.3
software. Differences between cases and controls were calculated by
using the WMD for continuous variables and were illustrated by a
forest plot. Random-effects model was employed to obtain an
average effect size and to study heterogeneity. Statistical heteroge-
neity between studies was assessed with Chi-square heterogeneity
statisticQ and then quantiﬁed with I2. P< .1 or I2>50% revealed
signiﬁcant heterogeneity among studies.[27,28] When standard error
of the mean (SEM) was only reported, standard deviation (SD) was
estimatedusing the following formula: SD=SEM sqrt(n),where n
is the number of subjects. A P value less than .05 was considered
signiﬁcant for all statistical tests.
2.5. Sensitivity analyses
Our sensitivity analysis was performed by leave-one-out
approach.[29]
2.6. Patient and public involvement
No patients or the public were involved in this study.
3. Results
3.1. Characteristics of included studies
Three hundred twenty-ﬁve publications were found during the
initial literature search. Of which, 47 were excluded for duplicate
studies and 245 papers were excluded by reading their title and
abstract (see the detail in Fig. 1). The remaining 8 studies were
included in the ﬁnal review.[21,30–36] The main characteristics of
the 8 included studies are shown in Table 1. These studies were
published between 1990 and 2017. In the 8 studies, 717 SLE
patients were included (336 cases in CQ or HCQ group and 381
cases in control group). Of which, 2 experimental of studies used
CQ,[33,34] 2 experimental of studies used HCQ or CQwhile there
was not detailed statement,[31,32] 4 experimental of studies used
HCQ.[21,30,35,36] The overall patients were unbalanced in gender
composition with more females than males.
3.2. Quality assessment
Figure 2 and Table 1 show a risk-of-bias made for the studies
included. There are some unclear items in 2 RCTs. No
observational studies obtain the score of 9 stars, 2 studies scored
7, 3 scored 6, 1 scored 4. Therefore, themethodological quality of
studies included here was not satisﬁed.
Figure 1. Schematic representation of the literature identiﬁcation and selection process.
Tao et al. Medicine (2019) 98:14 www.md-journal.com3.3. Meta-analysis resultsFigure 3 shows the pooled results from the random-effects model
combing the WMD for serum lipids. CQ or HCQ’s effect on SLE
serum lipids was reported in 2 RCTs, 2 cohort studies and 4 case-
control studies. Among them, 8 of the studies assessed TC, 7 of
the studies assessed TG, LDL-C, HDL-C and 5 of the studies
assessed VLDL-C.
The systematic review andmeta-analysis suggested that the CQ
or HCQ therapy reduce the level of serum TC (WMD=21.40
mg/dL, 95%CI27.62 to15.18, P< .00001; I2=0%, P= .71).3TG (WMD=29.07mg/dL, 95% CI 45.28 to 12.86,
P= .0004; I2=48%, P= .07). LDL-C (WMD=16.25mg/dL,
95%CI 28.82 to 3.68, P= .01; I2=73%, P= .001), HDL-C
(WMD=4.42mg/dL, 95%CI1.21 to 10.06, P= .12; I2=70%,
P= .003). VLDL-C (WMD=6.41mg/dL, 95% CI 12.39 to
0.44, P= .04; I2=67%, P= .02).3.4. Subgroup and sensitivity analysis
We repeated the primary analyses among subgroups deﬁned by:
drugs (RCTs or observational studies). Table 2 shows the results
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Figure 2. Quality assessment of the included RCTs. RCTs = randomised controlled trials.
Tao et al. Medicine (2019) 98:14 www.md-journal.comof subgroup analysis for serum lipids. The ﬁnding of antima-
larials decreased serum lipids (TC, TG, LDL-C, VLDL-C) in SLE
patients was consistently found in most subgroup analysis.
Our sensitivity analysis indicates that excluding one study at a
time does not make a signiﬁcant difference on TC, TG, LDL-C,
HDL-C. None of the results was signiﬁcantly altered, conﬁrming
that the result was robust.53.5. Publication bias
There was signiﬁcant asymmetry in the funnel plot for the
effect of CQ or HCQ on TG, LDL-C, HDL-C, VLDL-C, which
may be due to publication bias and other causes and no
publication bias was found for the effect of CQ or HCQ on
TC (Fig. 4).
Figure 3. Meta-analysis of the results.
Tao et al. Medicine (2019) 98:14 Medicine4. Discussion
To the best of our knowledge, this is the ﬁrst meta-analysis to
explore the effect of CQ orHCQonTC, TG, LDL-C,HDL-C and
VLDL-C in SLE patients. A total of 8 studies, predominantly
reporting low level of evidence (2 RCTs, 2 cohort studies, 4 case-
control studies) were included in this study. Overall, we
quantitatively summarize all the available evidences and ﬁnd6that HCQ or CQ therapy could signiﬁcantly decrease the serum
TC, TG, LDL-C, VLDL-C by 21.40mg/dL, 29.07mg/dL, 16.25
mg/dL, 6.41mg/dL, respectively, but not HDL-C in comparison
of control group. We found that the trend varied a little in
subgroup analyses.
Although the treatments of SLE vary, antimalarials were
still considered as the basic drugs in SLE patients.[37,38] Some
Table 2
The results of subgroup analyses.
Studies No. of studies Total sample size WMD (mg/dL) 95% CI (mg/dL) Heterogeneity I2
1. Subgroup outcomes of TC (different drugs)
CQ 2 49 15.95 28.49 to 3.41 0
HCQ 4 163 21.05 30.93 to 11.17 0
AM (CQ or HCQ) 2 505 25.55 35.96 to 15.13 0
2. Subgroup outcomes of TG (different drugs)
CQ 2 49 48.22 82.76 to 13.67 45%
HCQ 4 163 17.50 42.96 to 7.95 58%
AM (CQ or HCQ) 1 123 36.30 63.71 to 8.89 –
3. Subgroup outcomes of LDL-C (different drugs)
CQ 2 49 16.44 29.35 to 3.52 1%
HCQ 4 163 14.85 36.84 to 7.14 84%
AM (CQ or HCQ) 1 123 18.56 33.94 to 3.18 –
4. Subgroup outcomes of HDL-C (different drugs)
CQ 2 49 8.94 2.42 to 15.45 0
HCQ 4 163 3.18 6.52 to 12.88 81%
AM (CQ or HCQ) 1 123 0.39 5.43 to 6.21 –
5. Subgroup outcomes of VLDL-C (different drugs)
CQ 2 49 9.27 15.37 to 3.18 39%
HCQ 2 49 4.49 27.47 to 18.48 67%
AM (CQ or HCQ) 1 123 7.35 12.82 to 1.88 –
Tao et al. Medicine (2019) 98:14 www.md-journal.comrelevant studies have reported the inﬂuence of CQ or HCQ on
serum lipids in SLE patients. In 1997, Arthur Kavanaugh et al
reported a double-blind, randomized, placebo-controlled, pilot
study on 17 patients with SLE, the results showed a signiﬁcant
decrease in TC among patients receiving 400mg/day HCQ
(MD=11.6mg/dL, P= .03).[30] A recent meta-analysis also
reported the decrease of LDL-C after using HCQ, but this study
did not include other serum lipids in terms of TC, TG, HDL-C,
and VLDL-C, and could not give people a complete acknowledge
of the impact of AM on serum lipids in SLE patients. In 2017, Ali
Abdalla et al reported a case-control study about the impact of
HCQ on serum lipids, this study showed that there was no
signiﬁcant difference between the HCQ group and the control
group.[36]Figure 4. Funnel plots for the effect of CQ or HCQ on serum lipids in SLE pa
erythematosus.
7The mechanism of HCQ or CQ decreasing the serum lipid
among SLE patients remains unclear. In 1983, Sewell et al
reported that after chloroquine administration, the hepatic
activities of lysosomal enzymes (N-acetyl-beta-glucosaminidase,
beta-glucuronidase, and beta-galactosidase) were increased and
cholesterol saturation of bile decreased by 22% in rat.[39] In
1984, Chen et al reported that CQ treatment of rat cells in culture
results in the increase of hydroxymethylglutaryl coenzyme A
(HMG-CoA) reductase activity,[40] HMG-CoA reductase was a
rate limiting enzyme in the process of cholesterol synthetize in
hepatocytes. In 2007, Sachet et al reported that CQ can up-
regulation LDL-receptor, this is a very efﬁcient mechanism for
LDL reduction in SLE.[34] This up-regulation in LDL receptors
may be due to the CQ-mediated decrease in cholesteroltients. CQ=chloroquine, HCQ=hydroxychloroquine, SLE = systemic lupus
[41]
Tao et al. Medicine (2019) 98:14 Medicinesynthesis. More studies are needed to determine the mecha-
nism of CQ or HCQ decrease serum lipid.
Different studies had different results and conclusions, we
conducted a meta-analysis of relevant studies to further conﬁrm
the impact. The results showed that CQ or HCQ can decrease the
TC, TG, LDL-C, VLDL-C in SLE patients, and our ﬁndings are of
clinical signiﬁcance to some extent. CQ or HCQ can decrease the
serum lipids, which was the most risk factor results in
atherosclerosis and coronary heart disease (CAD). In 2014,
Meng et al reported that after 24 months’ using of HCQ, the level
of serum lipids reduced, and the left ventricular end diastolic
diameter and left ventricular posterior wall thickness decreased as
well.[35] We proposed that CQ or HCQ might be a beneﬁcial
choice in the prevention of CAD in lupus patients. To our best
knowledge, SLE patients have a more prevalent about athero-
sclerosis and CAD. Once diagnosed with CAD, patients were
probably to take several drugs lifelong. HCQ is a multi-
functional drug that contains the both beneﬁts of therapy SLE
and prevents CAD. In China, SLE patients from the onset to the
use of HCQ is still relatively interval a long time, we think that
should shorten the time. SLE patients may be more popular to
promote the use of HCQ.
Strengths of this meta-analysis included its exhaustive search
without language restrictions and validated systematic review
methods following the PRISMA guidelines. Several limitations of
this meta-analysis merit consideration. First, the characteristics of
populations, and the adjusted confounding factor were not
strictly described in some studies; however, these factors may
result in heterogeneity and have a potential impact on our results.
Second, since there were not enough RCTs for this meta-analysis,
the conclusion remains questionable for all the SLE population.5. Strength and limitations
5.1. Strength
This study exhaustive searched without language restrictions and
validated systematic review methods following the PRISMA
guidelines.5.2. Limitations(1) The characteristics of populations and the adjusted con-
founding factor were not strictly described in some studies.
However, these factors may result in heterogeneity and have a
potential impact on our results.
There were not enough RCTs for this meta-analysis, the(2)
conclusion remains questionable for all the SLE population.
6. Conclusions
Our results suggest that CQ or HCQ has the effect on reducing
the serum lipids in patients with SLE; however, these results
should be interpreted with cautions due to the signiﬁcant
heterogeneity in the study and limited RCTs. Further RCTs are
needed to conﬁrm this conclusion.
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